Inhibikase Therapeutics, Inc. (NYSE:IKT – Get Free Report)’s stock price traded down 0.3% during mid-day trading on Friday . The stock traded as low as $1.54 and last traded at $1.60. 10,251 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 89,473 shares. The stock had previously closed at $1.60.
Wall Street Analyst Weigh In
Separately, HC Wainwright decreased their price target on Inhibikase Therapeutics from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, May 21st.
Check Out Our Latest Stock Analysis on Inhibikase Therapeutics
Inhibikase Therapeutics Stock Performance
Inhibikase Therapeutics (NYSE:IKT – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.06. On average, research analysts anticipate that Inhibikase Therapeutics, Inc. will post -1.87 EPS for the current year.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Featured Articles
- Five stocks we like better than Inhibikase Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is the Shanghai Stock Exchange Composite Index?
- MarketBeat Week in Review – 7/22 – 7/26
- What is a Dividend King?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.